61
Views
5
CrossRef citations to date
0
Altmetric
Review

Efficacy and safety of programmed death 1 inhibitors in patients with advanced non-small cell lung cancer: a meta-analysis

, , , , , , & show all
Pages 4619-4630 | Published online: 21 May 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Binbin Zhang, Aiqun Xu, Dong Wu, Wanli Xia, Pulin Li, Enze Wang, Rui Han, Peng Sun, Sijing Zhou & Ran Wang. (2021) ARL14 as a Prognostic Biomarker in Non-Small Cell Lung Cancer. Journal of Inflammation Research 14, pages 6557-6574.
Read now
Lin Chen, Zhimou Cai, Kexing Lyu, Zhiwei Cai & Wenbin Lei. (2021) A novel immune-related long non-coding RNA signature improves the prognosis prediction in the context of head and neck squamous cell carcinoma. Bioengineered 12:1, pages 2311-2325.
Read now

Articles from other publishers (3)

Huihui Jiang, Aiqun Xu, Min Li, Rui Han, Enze Wang, Dong Wu, Guanghe Fei, Sijing Zhou & Ran Wang. (2022) Seven autophagy-related lncRNAs are associated with the tumor immune microenvironment in predicting survival risk of nonsmall cell lung cancer. Briefings in Functional Genomics 21:3, pages 177-187.
Crossref
Rui Han, Youhong Guan, Min Li, Aiqun Xu, Dong Wu, Pulin Li, Enze Wang, Peng Sun, Guanghe Fei, Sijing Zhou & Ran Wang. (2022) Efficacy and Safety of Nanoadministration in the Treatment of Non-Small-Cell Lung Cancer Is Good to Some Extent: A Systematic Review and Meta-Analysis. Journal of Oncology 2022, pages 1-11.
Crossref
Huihui Jiang, Aiqun Xu, Wanli Xia, Xingyuan Xia, Pulin Li, Binbin Zhang, Ke Zhu, Sijing Zhou & Ran Wang. (2021) Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis. Cancer Cell International 21:1.
Crossref